Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

BACKGROUND: The 5-year survival rate of patients with metastatic gastric cancer (GC) is only 5%. However, trials have demonstrated promising antitumor activity for targeted therapies/immunotherapies among chemorefractory metastatic GC patients. Pembrolizumab has shown particular efficacy among patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauren, Brianna, Ostvar, Sassan, Silver, Elisabeth, Ingram, Myles, Oh, Aaron, Kumble, Lindsay, Laszkowska, Monika, Chu, Jacqueline N., Hershman, Dawn L., Manji, Gulam, Neugut, Alfred I., Hur, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048937/
https://www.ncbi.nlm.nih.gov/pubmed/32148492
http://dx.doi.org/10.1155/2020/2198960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048937/
https://www.ncbi.nlm.nih.gov/pubmed/32148492
http://dx.doi.org/10.1155/2020/2198960

Ejemplares similares